SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

Satoshi Nakamoto is trending as community members highlight the tokenization of the pseudonymous Bitcoin creator as a monumental narrative with limitless potential. Many believe that owning $SATOSHI is akin to owning a piece of crypto culture itself, and that it could become the 'Bitcoin of memes'. The community expresses strong conviction and excitement for its future.

Sociedad Quimica y Minera de Chile SA engages in the production and distribution of fertilizers, potassium nitrate, iodine, and lithium chemicals. It operates through the following segments: Specialty Plant Nutrients, Iodine and Derivatives, Lithium and Derivatives, Industrial Chemicals, Potassium, and Other Products and Services. The Specialty Plant Nutrients segment produces potassium nitrate, sodium nitrate, sodium potassium nitrate, and specialty blends. The Iodine and Derivatives segment manufactures iodine and iodine derivatives, which are used in a wide range of medical, pharmaceutical, agricultural, and industrial applications. The Lithium and Derivatives segment covers lithium carbonate for electrochemical materials for batteries, frits for the ceramic and enamel industries, heat-resistant glass, air conditioning chemicals, continuous casting powder for steel extrusion, primary aluminum smelting process, pharmaceuticals, and lithium derivatives. The Industrial Chemicals segment comprises industrial chemicals including sodium nitrate, potassium nitrate, and boric acid. The Potassium segment produces potassium chloride and potassium sulfate. The Other Products and Services segment deals with other fertilizers and blends. The company was founded on June 17, 1968 and is headquartered in Santiago, Chile.

Sociedad Quimica Y Minera de Chile S.A. - ADR

Chemical & Mining Co. of Chile Inc.

SQM is garnering attention as community members discuss its potential as a retail squeeze candidate amid fluctuating lithium prices and Rothschild's updated neutral rating. An outstanding article highlights SQM's current state, while analysts discuss lithium demand potentially outpacing supply later this decade. Recent unusual options activity suggests bullish sentiment for the stock.

ACM Research, Inc. engages in the development, manufacture, and sale of single-wafer wet cleaning equipment. It supplies process solutions that semiconductor manufacturers can use in numerous manufacturing steps to remove particles, contaminants and other random defects, and thereby improve product yield. The company tools can be used in fabricating foundry, logic and memory chips including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company was founded by David H. Wang and Hui Wang in January 1998 and is headquartered in Fremont, CA.

ACM Research Inc - Ordinary Shares - Class A

ACMR is gaining attention as a potential retail squeeze candidate, with community members highlighting its undervalued status and overlooked potential. Bullish sentiment is further fueled by discussions around pre-released revenue and the value of ACMR's stake in its Shanghai entity. The stock's performance relative to its Chinese subsidiary and the broader semiconductor sector is a key talking point.

zkSync

ZK Crypto (zkSync) is trending as the community discusses its potential and future outlook, with attention being drawn to recent technology advancements and integrations, including EVM equivalence and enterprise chain solutions. Community members are actively speculating on potential price movements and expressing bullish sentiment. Some are attributing the increased interest to endorsements and integrations with major financial institutions.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class B

Fox Corporation - Class B

FOX is trending due to a mix of factors, including discussions about potential retail squeezes and exclusive content partnerships by Tubi Media Group. Recent earnings exceeding expectations and analyst upgrades are contributing to the stock's momentum. Community members are also actively evaluating options strategies and discussing technical indicators, alongside broader debates about media bias.

NetApp, Inc. engages in the provision of software, systems, and services to manage and share data on-premises. The firm also offers private and public clouds worldwide. It operates through the Hybrid Cloud and Public Cloud segments. The Hybrid Cloud segment provides a data storage portfolio for storage management and infrastructure solutions. The Public Cloud segment refers to a portfolio of products delivered primarily as-a-service. The company was founded by David Hitz, James K. Lau, and Michael Malcolm in April 1992 and is headquartered in San Jose, CA.

Netapp Inc

NetApp is trending amid discussions around its AI strategy and potential as a "major retail squeeze candidate". Community members are weighing its growth prospects against competitors like Western Digital, while also analyzing call option opportunities and target prices. Recent news highlights NetApp's AI-driven innovations and partnerships, particularly with Nvidia, fueling optimism around its role in the evolving data storage landscape.

Zepp Health Corp. engages in the development of smart wearable health and consumer fitness devices. It empowers users to achieve their well-being goals by optimizing their health, fitness, and wellness journeys. Its brands include Amazfit, Zepp Clarity, and Zepp Aura. The company was founded by Huang Wang in 2013 and is headquartered in Gorinchem, Netherlands.

Zepp Health Corporation - ADR

Huami Corp

ZEPP is trending amid discussions about its potential as a leading AI wearables company and a "Garmin killer," with some anticipating strong growth and a short squeeze. Bullish sentiment is fueled by positive product reviews, rising demand, and strategic investments, while bears cite concerns about valuation and profitability, creating a volatile trading environment. Some analysts anticipate a strong Q3, which could drive the stock higher.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending due to buyout speculation, with major shareholders proposing a take-private deal at $18 per share, creating significant community buzz around a potential near-term return. Discussions also involve the possibility of short squeezes given the stock's high short interest. Some traders are weighing in on whether minority shareholders will get a fair deal.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending as analysts turn bullish following recent financial results and upgrades from Goldman Sachs and Macquarie, with community members discussing potential for a turnaround. Speculation includes possible AI integration and a potential short squeeze, with some comparing PTON's potential to Carvana's comeback. However, others remain skeptical, citing a challenging macroeconomic environment and past disappointments.

Mercury Systems, Inc. is a technology company, which engages in the delivery of processing technology for aerospace and defense missions. Its processing technologies include signal solutions, display, software applications, networking, storage, and secure processing. It operates through the following geographical segments: US, Asia Pacific, and Europe. The company was founded on July 14, 1981 and is headquartered in Andover, MA.

Mercury Systems Inc

Mercury Systems ($MRCY) is trending as investors weigh recent earnings, analyst ratings, and community discussion of a potential retail squeeze. Upcoming earnings are generating bullish sentiment, while unusual options activity suggests potential upside. The defense sector's strength and strategic partnerships are also being considered in the broader context of MRCY's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Company News for Oct 31, 2025

Companies in The News Are: WDC,LLY,IP,CAH

Meta investors think Mark Zuckerberg is living dangerously, says Jim Cramer

'Mad Money' host Jim Cramer recaps earnings for Apple, Amazon, Eli Lilly, Meta and more...

Jim Cramer recaps Thursday's slate of earnings and what they signal about the economy

'Mad Money' host Jim Cramer recaps earnings for Apple, Amazon, Eli Lilly, and more...

Mizuho's Holtz talks what is behind Novo's bid for Metsera

Jared Holz, Mizuho, joins 'Fast Money' to recap Novo Nordisk's bid for Metsera and ELi Lilly soaring after earnings beat...

We're raising our Eli Lilly price target what a difference a quarter makes

The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications...

Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales 

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.

<ul class="summary-bullets"><li>Eli Lilly CEO Dave Ricks' comments come after the company reported third-quarter earnings results that topped estimates and hiked its full-year guidance.</li><li>Ricks stated “triple-acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.</li><li>In addition to its injectable therapies, the launch of Orforglipron, a daily oral pill for weight loss, is also in the pipeline.</li></ul>Eli Lilly (LLY) is reportedly looking to expand into pain relief by leveraging the momentum of its weight loss treatments, Mounjaro and Zepbound, which have captured significant share in the fast-growing obesity market.CEO Dave Ricks&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/video/2025/10/30/watch-cnbcs-full-interview-with-eli-lilly-ceo-dave-ricks.html">told</a> CNBC on Thursday that the company sees potential to move beyond traditional weight management into therapies that address pain associated with obesity. According to the company’s third-quarter earnings report, trials are underway targeting knee and back pain, with a focus on patients who are overweight or have obesity.<blockquote>“We hope to prove that patients who are overweight or have obesity with chronic knee pain find relief with Retatrutide in addition to losing weight.”&nbsp;– Dave Ricks, CEO, Eli Lilly</blockquote>Ricks stated “triple acting” Retatrutide promises to have an even bigger impact on weight loss than Zepbound and Mounjaro.&nbsp; “The first study that we’ll read out for that triple-acting agent will actually be in knee pain,” he said, adding that weight loss drugs have both direct and indirect anti-inflammatory effects.<h2 class="st-heading-2">Eli Lilly Hikes Full-Year Guidance</h2>Ricks’ comments follow the company's upbeat third-quarter (Q3) results and increased full-year guidance, issued earlier on Thursday. The pharmaceutical giant now expects its fiscal 2025 revenue to be between $63 billion and $63.5 billion, up from its previous guidance of $60 billion to $62 billion.<a href="http://stocktwits.com/symbol/LLY">LLY’s stock</a> gained 3.7% in morning trade, with retail sentiment around the pharma giant on Stocktwits improving to ‘bullish’ from ‘bearish’ territory over the past day. Retail chatter increased to ‘high’ from ‘low’ levels.Lilly reported a strong international uptake for its products, rolling out Mounjaro earlier this year in markets including India, China, and Brazil. “We’re seeing global demand for this product,” the CEO said, adding that both Mounjaro and Zepbound have performed well in their early years, signaling the potential for sustained growth in the future.<h2 class="st-heading-2">Oral Pill Expansion</h2>In addition to its injectable therapies, Lilly is preparing to launch Orforglipron, a daily oral pill, which Ricks said has completed Phase 3 trials, with submission expected in Q4. The CEO highlighted that oral therapy meets patient demand for a less intrusive option than weekly injections.&nbsp;He said it also addresses practical barriers in middle-income countries where refrigeration and cold-chain requirements limit access to injectable products. “We think that’s a great spot for Orforglipron,” the CEO noted, adding that the company expects strong global performance for Orforglipron.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-dips-triggers-800-million-in-crypto-liquidations-after-powells-warning/cLGFrJnR3Dy">Bitcoin Dips, Triggers $800 Million In Crypto Liquidations After Powell’s December Warning</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of New York on March 12, 2024 in New York City. (Photo by Spencer Platt/Getty Images)

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide 

CEO Dave Ricks told CNBC that the first study the company plans to read out for Retatrutide will be on knee pain.

Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide

Equity

Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro

Eli Lilly chairman and CEO David Ricks joins CNBC's Squawk on the Street team to discuss its quarterly earnings report that beat estimates, weight loss drug demand, its drug pipeline and more...

Pre-markets Down on Questions: Fed, Jobs & Q3 Earnings

Weekly Jobless Claims are not out again this Thursday morning, for the fifth straight week.

Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LLY News

LLYLilly(Eli) & Co